MarketInOut Stock Screener Log In | Sign Up
 

Aprea Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/06/2026 13:30
Aprea Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8.75 mln
Float11.46 mln
Earnings Date11/05/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-35.12
Highly reliable

1-Year Forecast

3.73
Transformational upside

Relative Strength

14 / 100
Significantly lagging

Pre-Tax Margin

-237,363%
Severely loss-making

ROE

-50.87
Deeply negative

Business Description

Aprea Therapeutics is a Pennsylvania-based company working to bring new cancer treatments to patients. The company is currently testing two experimental drugs in early-stage clinical trials ? one targeting a protein called WEE1 and another targeting ATR ? both designed to fight solid tumors by disrupting the way cancer cells repair their DNA. Its approach focuses on exploiting specific weaknesses in cancer cells to slow or stop tumor growth.

Key Fundamentals

EPS-0.91
ROE-50.87
ROIC-1,289
ROA-44.60
EBITDA, mln-12.28
EV / EBITDA-0.15
EV / EBIT-0.15
Revenue, mln0.00
EV / Revenue381

Quote Details

Last 0.643
Change -0.0326 (-4.83%)
Open 0.68
Volume 118,418
Turnover 76,143
Average Volume 249,822

Financial Ratios

Pre-Tax Profit Margin-237,363
Leverage Ratio1.10
Current Ratio13.55
Price / Book0.24
Price / Tangible Book0.24
Price / Sales17.05

Financial Strength

Altman Z-Score-9.25
Piotroski F-Score 3 / 9
Beneish M-Score-35.12
1-Year Target Price3.73
Short Ratio1.03
Short % of Float4.84

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -16.45% 4 / 100   
1 Month -19.05% 13 / 100   
2 Months -19.86% 22 / 100   
6 Months -9.56% 27 / 100   
1 Year -57.13% 15 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us